VACCINEX INC (VCNX) Stock Price, Quote, News and Overview
NASDAQ:VCNX - Nasdaq - US9186403013 - Common Stock - Currency: USD
VCNX Quote, Performance and Key Statistics
1.41
-2.24 (-61.37%)
The current stock price of VCNX is 1.41 USD. In the past month the price decreased by -54.66%. In the past year, price decreased by -85.66%.
VCNX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.97 | 326.55B | ||
| AMGN | AMGEN INC | 12.81 | 142.94B | ||
| GILD | GILEAD SCIENCES INC | 12.52 | 120.65B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 109.26B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.91 | 56.98B | ||
| ARGX | ARGENX SE - ADR | 93.64 | 33.56B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.67B | ||
| ONC | BEIGENE LTD-ADR | 5.79 | 25.01B | ||
| BNTX | BIONTECH SE-ADR | N/A | 22.30B | ||
| NTRA | NATERA INC | N/A | 20.66B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.79B | ||
| BIIB | BIOGEN INC | 7.47 | 17.32B |
Related stock screener links
About VCNX
Company Profile
Vaccinex, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Rochester, New York and currently employs 37 full-time employees. The company went IPO on 2018-08-09. The firm is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including neurodegenerative diseases, cancer, and autoimmune disorders. Its lead product candidate, pepinemab, is in clinical development for the treatment of Alzheimer’s disease, head and neck, pancreatic and breast cancer. Its lead platform technologies include SEMA4D antibody platform and ActivMAb antibody discovery platform. SEMA4D antibody platform is the application of its knowledge of SEMA4D biology to develop pepinemab for the treatment of various diseases and conditions, including cancer. ActivMAb antibody discovery platform is a human antibody discovery platform based on a method for expressing multipass membrane proteins, as well as large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface of mammalian pox viruses.
Company Info
VACCINEX INC
1895 Mount Hope Ave
Rochester NEW YORK 14620 US
CEO: Maurice Zauderer
Employees: 39
Phone: 15852712700
VACCINEX INC / VCNX FAQ
What is the stock price of VACCINEX INC today?
The current stock price of VCNX is 1.41 USD. The price decreased by -61.37% in the last trading session.
What is the ticker symbol for VACCINEX INC stock?
The exchange symbol of VACCINEX INC is VCNX and it is listed on the Nasdaq exchange.
On which exchange is VCNX stock listed?
VCNX stock is listed on the Nasdaq exchange.
What is VACCINEX INC worth?
VACCINEX INC (VCNX) has a market capitalization of 3.78M USD. This makes VCNX a Nano Cap stock.
How many employees does VACCINEX INC have?
VACCINEX INC (VCNX) currently has 39 employees.
Should I buy VACCINEX INC (VCNX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of VCNX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of VCNX, evaluating the profitability, health, valuation and growth aspects
- VACCINEX INC (VCNX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- VACCINEX INC (VCNX) Sales and EPS estimates to see what analysts future expectations are.
- VACCINEX INC (VCNX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- VACCINEX INC (VCNX) Insider and Institutional Ownership to learn about the owners and their transactions.
- VACCINEX INC (VCNX) Stock Chart to make your own analysis
- VACCINEX INC (VCNX) Latest news and press-releases to stay up to date.
Does VACCINEX INC (VCNX) stock pay dividends?
VCNX does not pay a dividend.
What is the Price/Earnings (PE) ratio of VACCINEX INC (VCNX)?
VACCINEX INC (VCNX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-12.16).
What is the Short Interest ratio of VACCINEX INC (VCNX) stock?
The outstanding short interest for VACCINEX INC (VCNX) is 0.16% of its float. Check the ownership tab for more information on the VCNX short interest.
VCNX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to VCNX. When comparing the yearly performance of all stocks, VCNX is a bad performer in the overall market: 99.22% of all stocks are doing better.
VCNX Financial Highlights
Over the last trailing twelve months VCNX reported a non-GAAP Earnings per Share(EPS) of -12.16. The EPS increased by 85.54% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -382.72% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
VCNX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to VCNX. The Buy consensus is the average rating of analysts ratings from 7 analysts.